HR

SABCS 2025: Redefining Endocrine-Based Care in HR+, HER2-Negative Breast Cancer Across Early and Metastatic Settings

Key data from SABCS 2025 highlight how endocrine-based, biology-driven strategies continue to reshape the management of ER-positive, HER2-negative breast cancer. This article reviews pivotal adjuvant...

Latest Post

Verzenio Demonstrates Overall Survival Benefit in High-Risk Early Breast Cancer: Seven-Year monarchE Results

Two years of Verzenio plus endocrine therapy shows OS benefit in high-risk HR+, HER2- early...

Verzenio Achieves Overall Survival Milestone in Early Breast Cancer Competition”

Verzenio plus endocrine therapy offers statistically significant OS improvements over endocrine therapy alone in high-risk...

Palbociclib Resistance Biomarkers in Advanced Breast Cancer

ctDNA genotyping reveals ESR1, PIK3CA mutations and CCND1, FGFR1 amplifications predict worse outcomes with palbociclib...

Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial

Dalpiciclib + ET significantly improved iDFS in HR+/HER2- early breast cancer: 24-month rates 94.7% vs...

Breast Cancer Insight Center

HER2

Triple Negative Breast Cancer (TNBC)

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest